Cereno Scientific Valuation

Is CRNO B undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CRNO B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CRNO B's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CRNO B's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CRNO B?

Key metric: As CRNO B is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CRNO B. This is calculated by dividing CRNO B's market cap by their current revenue.
What is CRNO B's PS Ratio?
PS Ratio	20.5x
Sales	SEK 68.72m
Market Cap	SEK 1.41b

CRNO B key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	20x
Enterprise Value/EBITDA	-22x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CRNO B's PS Ratio compare to its peers?

The above table shows the PS ratio for CRNO B vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	13.5x
EGTX Egetis Therapeutics	27.6x	81.7%	SEK 1.9b
DVYSR Devyser Diagnostics	11x	31.3%	SEK 2.2b
HNSA Hansa Biopharma	10.7x	47.3%	SEK 2.0b
PROB Probi	4.7x	5.3%	SEK 2.9b
CRNO B Cereno Scientific	20.5x	-171.4%	SEK 1.4b

Price-To-Sales vs Peers: CRNO B is expensive based on its Price-To-Sales Ratio (20.5x) compared to the peer average (13.5x).

Price to Sales Ratio vs Industry

How does CRNO B's PS Ratio compare vs other companies in the SE Biotechs Industry?

6 Companies	Price / Sales	Estimated Growth	Market Cap
XBRANE Xbrane Biopharma	1.5x	61.1%	US$27.20m
SPRINT Sprint Bioscience	1.7x	27.6%	US$9.38m
PMDS PMD Device Solutions	0.8x	62.0%	US$3.07m
GEAN Genetic Analysis	1.5x	n/a	US$2.63m

6 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: CRNO B is expensive based on its Price-To-Sales Ratio (20.5x) compared to the Swedish Biotechs industry average (11.8x).

Price to Sales Ratio vs Fair Ratio

What is CRNO B's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CRNO B PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	20.5x
Fair PS Ratio	0.002x

Price-To-Sales vs Fair Ratio: CRNO B is expensive based on its Price-To-Sales Ratio (20.5x) compared to the estimated Fair Price-To-Sales Ratio (0x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Swedish Orphan Biovitrum

SEK 103.1b

An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.

SOBI

SEK 300.20

-8.5%

24.2%

Corline Biomedical

SEK 139.3m

Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.

CLBIO

SEK 6.48

-7.7%

-44.1%

Camurus

SEK 32.1b

A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally.

CAMX

SEK 546.00

-12.2%

22.4%